CIS Pharma announces the first milestones in its ADC research program are achieved
Bubendorf, Switzerland, Thursday, January 21, 2016 - Proof of concept studies at NBE Therapeutics demonstrated conjugation of CIS Pharma’s Cellophil® Smart Polymer drug carrier to antibodies. Consequently, different linkers were evaluated for loading the drug carrier with anti-cancer moieties. CIS Pharma has successfully loaded its proprietary Cellophil® Smart Polymer drug carriers with model compounds for cancer therapies. CIS Pharma [...]
CIS Pharma creates novel contact lens coating technology
Bubendorf, Switzerland, Tuesday, November 17, 2015 - CIS Pharma is expanding its Cellophil® Smart Polymer platform with new bio-inspired derivatives. The derivatives are used as building blocks for the development of a novel contact lens coating technology. The Cellophil® Smart Polymer coating technology aims to improve the wettability of silicone hydrogel contact lenses. In addition, the coating is designed to [...]
CIS Pharma team attends CPhI Worlwide 2015 in Madrid
Madrid, Spain, Tuesday to Thursday, October 13 to 15, 2015 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Madrid. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]
CIS Pharma develops solubilization technology for hydrophobic drugs
Bubendorf, Switzerland, Tuesday, September 2, 2015 - CIS Pharma has engaged in a research program to develop a new technology platform that creates water-soluble formulations of highly hydrophobic drugs. The approach comprises a polymer-based solubilization technology that can be applied to a large number of water-insoluble drugs. The technology aims to improve the bioavailability and tolerance for drugs used in [...]
Submission of marketing authorization application for intracameral cefuroxime completed
Uppsala, Sweden, July 20, 2015 – CIS Pharma has submitted to the Swedish competent authority MPA the marketing authorization application for intracameral cefuroxime. The decentralized procedure is led by Sweden as reference member states with a total of seventeen reference member states across Europe. The CIS Pharma team is proud to have achieved the first major milestone in the agreement [...]
CIS Pharma creates next generation contact lens care products
Bubendorf, Switzerland, Friday, June 12, 2015 - CIS Pharma is investigating novel formulations and combinations of active ingredients to improve contact lens care. With over 25 years of experience and a track record of several lens care products licensed to and sold by partners globally, the team is targeting a novel concept that allows for higher contact lens wear comfort [...]
CIS Pharma appoints Davide Panighetti to its cancer research team
Bubendorf, Switzerland, Monday, March 23, 2015 - CIS Pharma welcomes Davide Panighetti, who reinforces the research team as a new synthesis chemist. Davide’s skills will boost the team working on proprietary polymer-drug carrier developed for antibody-drug conjugates and antibody-radionuclide conjugates. The polymer-drug carriers are based on the CIS Pharma's proprietary polymer technology allowing ADCs to be custom designed for delivery [...]
CIS Pharma team attends Pharmapack 2015 in Paris
Paris, France, Wednesday to Thursday, February 11 to 12, 2015 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]
CIS Pharma to develop drug carriers for ADCs
Bubendorf, Switzerland, Monday, January 12, 2015 - CIS Pharma has taken a strategic decision to extend its activity into the field of cancer treatments. The defined objective is to improve the potency of antibody-drug conjugates (ADCs). Having established a number of lead materials, the research team is now developing drug carriers that offer higher drug load per antibody as compared [...]
CIS Pharma signs development and licensing agreement with marketing partner for cefuroxime
Bubendorf, Switzerland, October 12, 2014 – CIS Pharma signs development and licensing agreement with licensee. Having developed intracameral cefuroxime as a response to the clinical demand for such a product, CIS Pharma is proud to have signed a deal on the regulatory approval and distribution of its product. Also, the deal includes a license to CIS Pharma’s patent protected cefuroxime [...]